School of Materials Science, Japan Advanced Institute of Science and Technology, Ishikawa, Japan.
Department of Veterinary and Animal Sciences, Faculty of Agriculture, University of Rajshahi, Rajshahi-6205, Bangladesh.
Gene Ther. 2017 Dec;24(12):779-786. doi: 10.1038/gt.2017.90. Epub 2017 Dec 7.
Site-directed RNA editing is an important technique for correcting gene sequences and ultimately tuning protein function. In this study, we engineered the deaminase domain of adenosine deaminase acting on RNA (ADAR1) and the MS2 system to target-specific adenosines, with the goal of correcting G-to-A mutations at the RNA level. For this purpose, the ADAR1 deaminase domain was fused downstream of the RNA-binding protein MS2, which has affinity for the MS2 RNA. To direct editing to specific targets, we designed guide RNAs complementary to target RNAs. The guide RNAs directed the ADAR1 deaminase to the desired editing site, where it converted adenosine to inosine. To provide proof of principle, we used an allele of enhanced green fluorescent protein (EGFP) bearing a mutation at the 58th amino acid (TGG), encoding Trp, into an amber (TAG) or ochre (TAA) stop codon. In HEK-293 cells, our system could convert stop codons to read-through codons, thereby turning on fluorescence. We confirmed the specificity of editing at the DNA level by restriction fragment length polymorphism analysis and sequencing, and at the protein level by western blotting. The editing efficiency of this enzyme system was ~5%. We believe that this system could be used to treat genetic diseases resulting from G-to-A point mutations.
位点定向 RNA 编辑是一种重要的技术,可用于纠正基因序列,最终调整蛋白质功能。在这项研究中,我们设计了腺苷脱氨酶作用于 RNA(ADAR1)的脱氨酶结构域和 MS2 系统,以靶向特定的腺苷,目标是在 RNA 水平上纠正 G 到 A 的突变。为此,将 ADAR1 脱氨酶结构域融合到 MS2 RNA 结合蛋白的下游,MS2 对 MS2 RNA 具有亲和力。为了将编辑导向特定的靶标,我们设计了与靶标 RNA 互补的向导 RNA。向导 RNA 将 ADAR1 脱氨酶引导至所需的编辑位点,在该位点将腺苷转换为肌苷。为了提供原理证明,我们使用了一个增强型绿色荧光蛋白 (EGFP) 的等位基因,该基因在第 58 个氨基酸(TGG)处发生突变,编码色氨酸,突变为琥珀(TAG)或赭石(TAA)终止密码子。在 HEK-293 细胞中,我们的系统可以将终止密码子转换为通读密码子,从而使荧光开启。我们通过限制性片段长度多态性分析和测序在 DNA 水平上证实了编辑的特异性,并通过 Western blot 在蛋白质水平上证实了编辑的特异性。该酶系统的编辑效率约为 5%。我们相信,该系统可用于治疗由 G 到 A 点突变引起的遗传疾病。